Neisseria meningitidis is a major cause of endemic cases and epidemics of meningitis and
devastating septicemia. Although effective vaccines exist for several serogroups of …

No broadly effective vaccines are available for prevention of group B meningococcal
disease, which accounts for> 50% of all cases. The group B capsule is an autoantigen and …

The Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is the leading
target for next-generation vaccines against the disease-causing blood-stage of malaria …

Activation of the complement system and resulting opsonisation with C3b are key events of
the innate immune defense against infections. However, a wide variety of bacterial …

Neisseria meningitidis is a Gram-negative microorganism that exists exclusively in humans
and can cause devastating invasive disease. Although capsular polysaccharide-based …

The view that immunoglobulins function largely by potentiating neutralization, cytotoxicity or
phagocytosis is being replaced by a new synthesis whereby antibodies participate in all …

The sequence variability of protective antigens is a major challenge to the development of
vaccines. For Neisseria meningitidis, the bacterial pathogen that causes meningitis, the …

Serogroup B meningococcal (MenB) disease remains a serious public health problem for
which a cross-protective vaccine effective against a wide range of MenB isolates has not …

Certain pathogens recruit host complement inhibitors such as factor H (fH) to evade the
immune system. Microbial complement inhibitor-binding molecules can be promising …

Most invasive meningococcal disease in developed countries is caused by Neisseria
meningitidis with a serogroup B capsule. However, despite availability of vaccines for other …